Bio Rad Laboratories Inc
NYSE:BIO

Watchlist Manager
Bio Rad Laboratories Inc Logo
Bio Rad Laboratories Inc
NYSE:BIO
Watchlist
Price: 330.53 USD 0.66% Market Closed
Market Cap: 9.3B USD
Have any thoughts about
Bio Rad Laboratories Inc?
Write Note

Bio Rad Laboratories Inc
Net Change in Cash

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Bio Rad Laboratories Inc
Net Change in Cash Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Change in Cash CAGR 3Y CAGR 5Y CAGR 10Y
Bio Rad Laboratories Inc
NYSE:BIO
Net Change in Cash
-$46.2m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Thermo Fisher Scientific Inc
NYSE:TMO
Net Change in Cash
-$1.5B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-1%
Danaher Corp
NYSE:DHR
Net Change in Cash
-$9.7B
CAGR 3-Years
-45%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Mettler-Toledo International Inc
NYSE:MTD
Net Change in Cash
$1.9m
CAGR 3-Years
-60%
CAGR 5-Years
N/A
CAGR 10-Years
-25%
Agilent Technologies Inc
NYSE:A
Net Change in Cash
-$261m
CAGR 3-Years
N/A
CAGR 5-Years
21%
CAGR 10-Years
N/A
IQVIA Holdings Inc
NYSE:IQV
Net Change in Cash
$348m
CAGR 3-Years
287%
CAGR 5-Years
57%
CAGR 10-Years
26%
No Stocks Found

Bio Rad Laboratories Inc
Glance View

Market Cap
9.3B USD
Industry
Life Sciences Tools & Services
Economic Moat
None

Bio-Rad Laboratories Inc. began its journey in 1952 and has since positioned itself as a formidable player in the life sciences and clinical diagnostics sectors. Founded by David and Alice Schwartz, the company thrived on the burgeoning interest in biological research, carving a niche by supplying essential products to scientists and healthcare professionals. With its headquarters in Hercules, California, Bio-Rad has continually developed a suite of innovative solutions that cater to both academic research and the intricate needs of clinical diagnostics, paving its way to becoming a global leader. Their operations are distinctly bifurcated: Life Science, which focuses on products for gene expression, protein purification, and food safety, and Clinical Diagnostics, offering tools for blood testing and diabetes monitoring. The core of Bio-Rad’s business model lies in its ability to design and manufacture advanced technological products that streamline laboratory processes, making research and diagnostics more efficient and reliable. The Life Science segment generates revenue by selling reagents, lab instruments, and software that facilitate various laboratory protocols and experiments, assisting scientists in their pursuit of breakthroughs in biotechnology and pharmaceutical development. Meanwhile, the Clinical Diagnostics segment garners earnings through the provision of innovative testing and analysis tools that enable accurate disease diagnosis, blood analysis, and quality control. Guided by a robust infrastructure of research and development, the company continuously adapts to the evolving demands of science and healthcare, maintaining its fiscal health while reinforcing its reputation as a trusted provider in the global market.

BIO Intrinsic Value
385.57 USD
Undervaluation 14%
Intrinsic Value
Price

See Also

What is Bio Rad Laboratories Inc's Net Change in Cash?
Net Change in Cash
-46.2m USD

Based on the financial report for Sep 30, 2024, Bio Rad Laboratories Inc's Net Change in Cash amounts to -46.2m USD.

What is Bio Rad Laboratories Inc's Net Change in Cash growth rate?
Net Change in Cash CAGR 1Y
23%

Over the last year, the Net Change in Cash growth was 23%.

Back to Top